HRTX
Price
$2.14
Change
-$0.09 (-4.04%)
Updated
Apr 3 closing price
Capitalization
339.69M
38 days until earnings call
SYRE
Price
$13.96
Change
-$1.53 (-9.88%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
933.38M
34 days until earnings call
Ad is loading...

HRTX vs SYRE

Header iconHRTX vs SYRE Comparison
Open Charts HRTX vs SYREBanner chart's image
Heron Therapeutics
Price$2.14
Change-$0.09 (-4.04%)
Volume$1.02M
Capitalization339.69M
Spyre Therapeutics
Price$13.96
Change-$1.53 (-9.88%)
Volume$17.49K
Capitalization933.38M
HRTX vs SYRE Comparison Chart
Loading...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HRTX vs. SYRE commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HRTX is a Hold and SYRE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (HRTX: $2.14 vs. SYRE: $13.96)
Brand notoriety: HRTX and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HRTX: 57% vs. SYRE: 147%
Market capitalization -- HRTX: $339.69M vs. SYRE: $933.38M
HRTX [@Biotechnology] is valued at $339.69M. SYRE’s [@Biotechnology] market capitalization is $933.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HRTX’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • HRTX’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, HRTX is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HRTX’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • HRTX’s TA Score: 4 bullish, 4 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both HRTX and SYRE are a good buy in the short-term.

Price Growth

HRTX (@Biotechnology) experienced а -7.36% price change this week, while SYRE (@Biotechnology) price change was -21.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

HRTX is expected to report earnings on May 12, 2025.

SYRE is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($933M) has a higher market cap than HRTX($340M). HRTX YTD gains are higher at: 39.869 vs. SYRE (-40.034). HRTX has higher annual earnings (EBITDA): -5.06M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. HRTX (59.3M). SYRE has less debt than HRTX: SYRE (0) vs HRTX (178M). HRTX has higher revenues than SYRE: HRTX (144M) vs SYRE (0).
HRTXSYREHRTX / SYRE
Capitalization340M933M36%
EBITDA-5.06M-208.57M2%
Gain YTD39.869-40.034-100%
P/E RatioN/A1.72-
Revenue144M0-
Total Cash59.3M603M10%
Total Debt178M0-
FUNDAMENTALS RATINGS
HRTX vs SYRE: Fundamental Ratings
HRTX
SYRE
OUTLOOK RATING
1..100
704
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5392
P/E GROWTH RATING
1..100
10080
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HRTX's Valuation (71) in the Biotechnology industry is in the same range as SYRE (77) in the Pharmaceuticals Major industry. This means that HRTX’s stock grew similarly to SYRE’s over the last 12 months.

HRTX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that HRTX’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as HRTX (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to HRTX’s over the last 12 months.

HRTX's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for SYRE (92) in the Pharmaceuticals Major industry. This means that HRTX’s stock grew somewhat faster than SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as HRTX (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to HRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HRTXSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 17 days ago
84%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GAIGX22.42N/A
N/A
Gabelli International Growth A
GATCX39.44N/A
N/A
Gabelli Asset C
PIREX29.10N/A
N/A
Principal Real Estate Securities Inst
VGYAX27.70N/A
N/A
Vanguard Global Wellesley Income Admiral
DBIWX10.39N/A
N/A
DWS Global Macro R6

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-9.88%
BEAM - SYRE
48%
Loosely correlated
-10.93%
APGE - SYRE
47%
Loosely correlated
-7.61%
CGON - SYRE
46%
Loosely correlated
-15.74%
PRME - SYRE
46%
Loosely correlated
-10.06%
IDYA - SYRE
46%
Loosely correlated
-4.77%
More